Capmatinib effective in NSCLC with MET exon 14 skipping mutations

  • Wolf J & al.
  • N Engl J Med
  • 3 Sep 2020

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Capmatinib, a selective reversible inhibitor of MET tyrosine kinase, demonstrated effective antitumor activity in patients with advanced NSCLC and a MET exon 14 skipping mutation, especially those who were previously untreated.

Why this matters

Study design

  • Prospective, international, multiple-cohort, phase 2 GEOMETRY study.
  • 364 patients with advanced NSCLC received capmatinib.
  • Funding: Novartis Pharmaceuticals.

Key results

  • 97 patients had a MET exon 14 skipping mutation, and 210 had MET amplification.
  • Results in the MET exon 14 skipping mutation group:
    • Overall response was reported in 41% of previously treated patients and 68% of previously untreated patients (median duration of response, 9.7 and 12.6 months, respectively).
    • Median PFS was 5.4 months among previously treated patients and 12.4 months among previously untreated patients.
  • Results in MET amplification group:
    • Efficacy was limited in previously treated patients with MET amplification who had a gene copy number of
    • Among patients with a gene copy number of ≥10, overall response was reported in 29% of previously treated patients and 40% of previously untreated patients (median duration of response, 8.3 months and 7.5 months, respectively).
  • Grade 3-4 adverse events (AEs) reported in 67% of patients and serious AEs reported in 13%.

Limitations

  • Open-label study.